Mobia Medical reported third-quarter revenue of $15.6 million, a 73% increase from the prior year period, driven by broader adoption of its Vivistim System. The company achieved an 83.2% gross margin and raised its full-year 2026 revenue guidance to between $57.0 million and $57.5 million, up from the previous range of $54.0 million to $56.0 million. Net loss for the quarter was $17.3 million, or $0.52 per share, compared to a net loss of $11.4 million in the prior year period. The company also announced that its paired VNS therapy has been included in the updated 2026 AHA Guideline for stroke recovery. Mobia Medical is a medical device company developing implantable solutions to improve upper limb function in chronic ischemic stroke survivors.
